OCON Therapeutics

Company Overview

Snapshot

Founded in March 2011, OCON Therapeutics operates with 11–50 employees. The company has raised $24.5M across 8 funding rounds from 12 investors. In June 2024, OCON Therapeutics secured $10M in funding, with Rhia Ventures and Exerte Partners participating.

Business overview

OCON Therapeutics is a Health Tech & Life Sciences company focused on women's health. It develops, manufactures, and commercializes products based on its proprietary and patented intrauterine ball (IUB) platform. This platform, made from super-elastic nitinol alloy, is designed as a carrier for multiple drugs to the uterus to treat various conditions. The company's core products include the IUB Ballerine, and it is developing a pipeline of IUB-based products for indications such as abnormal uterine bleeding, heavy menstrual bleeding, myomas, fibroids, and infertility. OCON Therapeutics serves markets across Australia, Africa, Asia, Europe, Americas, South America, and China.

Strategic signal

In June 2024, OCON Therapeutics raised $10 million, signaling continued investor confidence in its innovative intrauterine drug delivery platform for women's health. This funding round, which included Rhia Ventures as a lead investor, indicates a strong market validation for the company's approach to addressing various gynecological conditions and expanding its product pipeline. The capital infusion is expected to accelerate the development and commercialization of its IUB-based solutions, reinforcing its position in the FemTech sector.

Company Intelligence Q&A

What is OCON Therapeutics' primary focus?

OCON Therapeutics focuses on women's health, developing and commercializing products based on its proprietary and patented intrauterine ball (IUB) platform for drug delivery.

When did OCON Therapeutics last raise funding?

In June 2024, OCON Therapeutics raised $10M in funding, with Rhia Ventures leading the round.

What is the IUB Ballerine?

The IUB Ballerine is OCON Therapeutics' flagship product, an intrauterine device made from super-elastic nitinol alloy designed for hormone-free contraception and drug delivery.

Has OCON Therapeutics received any industry recognition?

In May 2022, OCON Healthcare was awarded as a Technology Pioneer by the World Economic Forum.

What is the status of OCON Therapeutics?

OCON Therapeutics is currently non-active, having ceased to operate in April 2026.